Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Predictors of Health-Related Quality of Life in Adults With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
In plain language
This study is for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, two types of blood cancer. It compares two types of treatment to see how quality of life, tiredness, and symptoms change over 2 years.
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Who can join
- Have CLL confirmed by lab tests of cells or tissue.
- Be within 7 days of starting one of these treatments: a BTK inhibitor, with or without an anti-CD20 antibody drug, or a BCL2 inhibitor with obinutuzumab. These drugs block proteins or target cancer cells.
- Be able to read and speak English or Spanish at an 8th-grade level.
Who can't join
- Have dementia, a condition that affects memory and thinking.
- Have a traumatic brain injury, meaning brain damage caused by an injury.
- Have leukemia that affects the brain or spinal cord.
Simplified for readability. The official criteria below are what the study team uses.
Official eligibility criteria
Inclusion Criteria: * All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included. * Subjects must be able to read and speak English or Spanish at the 8th grade level. Exclusion Criteria: * Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
Study sites (1)
FL
- Moffitt Cancer Center · Tampa, FL 33612Sara Tinsley-Vance, PhD, APRN, AOCN · Principal investigatorDorothie Durosier Mertilus, PhD · Sub-investigatorRichie Reich, PhD · Sub-investigatorMore trials in Tampa